|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
ZMYND10, an epigenetically regulated tumor suppressor, exerts tumor-suppressive functions via miR145-5p/NEDD9 axis in breast cancer.
|
31801619 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Quantitative RT‑PCR expression analysis also revealed that miR‑145‑5p was downregulated in four breast cancer cell lines relative to normal cells.
|
31002371 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the contribution of Ago2, the only human Ago protein endowed with nuclease activity, to the function of tumor-suppressor miR-145-5p in breast cancer (BC).
|
30622242 |
2019 |
|
Breast Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
MiR-145 was found to dose-dependently decrease messenger RNA and protein expression of HBXIP in breast cancer MCF-7 cells.
|
30381907 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis based on tumor type showed that the downregulation of miR-145 was associated with unfavorable OS in colorectal cancer (HR = 2.17; 95% CI, 1.52-3.08; <i>P</i> < 0.001), ovarian cancer (HR = 2.15; 95% CI, 1.29-3.59; <i>P</i> = 0.003), gastric cancer (HR = 1.78; 95% CI, 1.35-2.36; <i>P</i> < 0.001), glioma (HR = 1.65; 95% CI, 1.30-2.10; <i>P</i> < 0.001), and osteosarcoma (HR = 2.28; 95% CI, 1.50-3.47; <i>P</i> < 0.001).
|
30602498 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, decreased expression of hsa‑miR‑145 in OC and OC‑derived exosomes may be a crucial biomarker for the diagnosis and treatment of OC.
|
30365097 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
CTD_human |
Downregulation of miR-145-5p in cancer cells and their derived exosomes may contribute to the development of ovarian cancer by targeting CT.
|
30365097 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, miR‑145 was suggested to be a potential miRNA‑based therapeutic target in ovarian cancer.
|
30864742 |
2019 |
|
Carcinoma, Ovarian Epithelial
|
0.400 |
Biomarker
|
disease |
BEFREE |
Serum exosomal miR-145 in particular appeared to be the most promising biomarker for preoperative diagnosis of ovarian cancer.
|
31205555 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the high expression of TAGLN2 promoted cell proliferation and migration in BC. miR-145-5p appeared to regulate TAGLN2 in BC, and it also inhibited the cell proliferation and migration.
|
30405771 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
Circular RNA CEP128 acts as a sponge of miR-145-5p in promoting the bladder cancer progression via regulating SOX11.
|
30134837 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of the present study indicated that miRNA‑145 may function as a tumor suppressor and may have a potential to be a diagnostic and predictive biomarker, and a therapeutic target for treatment of BC.
|
29693148 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.400 |
Biomarker
|
disease |
CTD_human |
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
|
30026881 |
2018 |
|
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, the high expression of TAGLN2 promoted cell proliferation and migration in BC. miR-145-5p appeared to regulate TAGLN2 in BC, and it also inhibited the cell proliferation and migration.
|
30405771 |
2018 |
|
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results of the present study indicated that miRNA‑145 may function as a tumor suppressor and may have a potential to be a diagnostic and predictive biomarker, and a therapeutic target for treatment of BC.
|
29693148 |
2018 |
|
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
BEFREE |
Circular RNA CEP128 acts as a sponge of miR-145-5p in promoting the bladder cancer progression via regulating SOX11.
|
30134837 |
2018 |
|
Bladder Neoplasm
|
0.400 |
Biomarker
|
disease |
CTD_human |
A Panel of MicroRNA Signature as a Tool for Predicting Survival of Patients with Urothelial Carcinoma of the Bladder.
|
30026881 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
KCNQ1OT1 modulated CCNE2 through sponging miR-145 in BRCA.
|
30157476 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
LncRNA LINC01116 competes with miR-145 for the regulation of ESR1 expression in breast cancer.
|
29687853 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Expression of miR-206 is upregulated and expression of miR-145 is downregulated in breast cancer, which may have an impact on the prognosis of patients. miR-206 and miR-145 may serve as important indicators to predict prognosis of patients with breast cancer in the future.
|
30405803 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Moreover, miR-145-5p overexpression or p70S6K1 knockdown abrogated the oncogenic effects of circZNF609 in breast cancer.
|
30288120 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
MiR-145 affects breast cancer BS524 cell proliferation, infiltration, and migration via positively regulating OCT4 gene expression.
|
29565493 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
This study might serve as a significant platform for further research on miR-145 along with the ceRNA network in breast cancer.
|
29425746 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
This outcome revealed that MALAT1 promoted angiogenesis in BC, which may be related to the expression of miR‑145.
|
30226550 |
2018 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
In summary, the findings of this study, based on ceRNA theory, combining the research foundation of miR-145-5p and MMP11, and taking linc01561 as a new study point, provide new insight into molecular-level reversing proliferation and apoptosis of BrCa.
|
29890225 |
2018 |